<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03914586</url>
  </required_header>
  <id_info>
    <org_study_id>418/CE Lazio 1</org_study_id>
    <nct_id>NCT03914586</nct_id>
  </id_info>
  <brief_title>The Membrane Adsorbing OXiris Filter in Septic Patients With AKI</brief_title>
  <acronym>MOSAKI</acronym>
  <official_title>The OXIRIS Filter in Septic Shock : the Adsorption of Endotoxin and Cytokines Improves the Haemodynamic , the Renal Function , and the Metabolic Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FRANCO TURANI</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rome Tor Vergata</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with Sepsis / Septic Shock and AKI are submitted to Continuous Renal Replacement
      Therapy with the oXiris filter . The pro- inflammatory mediators , the endotoxin ,
      interleukin 10 , the main cardiorespiratory indices and renal parameters are evaluated at the
      entry of the study and at the end of the treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with a diagnosis of sepsis or septic shock Gram + , Gram - and acute renal failure
      All patients are submitted to Continuous Renal Replacement Therapy with the treated
      heparin-coated membrane (oXiris;Baxter );

        -  Citrate Anticoagulation or Heparin with thromboelasthograpy monitoring .

        -  Hemodynamic monitoring with dynamic parameters ( Cardiac Index ,Stroke Volume Variation
           , Pulse Pressure Variation ) and Echocardiography

        -  Indirect Calorimetry ( before Continuous Renal Replacement Therapy and after 1 hour
           stopping Continuous Renal Replacement Therapy )

        -  Laboratory: white blood cell, creatinine, procalcitonin, Interleukin -6, Interleukin
           -10, Endotoxin , Lactate, diuresis, tromboelastography (post filter and arterial sample
           ) and dosage of Plasminogen Activator Inhibitor -1 at the same sites.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2019</start_date>
  <completion_date type="Anticipated">July 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hemodynamic Data</measure>
    <time_frame>At the 24 - 48 hours after starting of the treatment</time_frame>
    <description>Changes of vasoactive drugs concentration (micr/Kg/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Data</measure>
    <time_frame>At the 24 - 48 hours after starting of the treatment</time_frame>
    <description>Changes of Urinary Out Put ( mL/ 24 hours)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory Data</measure>
    <time_frame>At the 24 - 48 hours after starting of the treatment</time_frame>
    <description>Changes of P/F ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calorimetric data</measure>
    <time_frame>At the 24 - 48 hours after starting of the treatment</time_frame>
    <description>Changes of VO2 (mL / min)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory data</measure>
    <time_frame>At the 24 - 48 hours after starting of the treatment</time_frame>
    <description>Changes of Endotoxin ( EAA measurement )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation data</measure>
    <time_frame>At the 24 - 48 hours after starting of the treatment</time_frame>
    <description>Changes of the PAI-1 ( ng /mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines Data</measure>
    <time_frame>At the 24 - 48 hours after starting of the treatment</time_frame>
    <description>IL 6 (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines data</measure>
    <time_frame>At the 24 - 48 hours after starting of the treatment</time_frame>
    <description>IL 10 (pg/mL)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Sepsis</condition>
  <condition>Acute Renal Failure</condition>
  <arm_group>
    <arm_group_label>Septic patients with AKI</arm_group_label>
    <description>Patients with sepsis /septic shock ( Sepsis III ) and AKI submitted to Continuous Renal Replacement Therapy with the adsorbing membrane oXiris.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>oXiris filter</intervention_name>
    <description>Continuous Renal Replacement Therapy with oXiris filter</description>
    <arm_group_label>Septic patients with AKI</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with sepsis /septic shock and AKI
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:- Age &lt;18 years 75 years &gt;

          -  Diagnosis of sepsis or septic shock (Sepsis III)

          -  Mechanical Ventilation or non Invasive ventilation with PaO2 /FIO2 &lt; 200.

          -  Renal failure ( AKI ≥ 1)

          -  Endotoxin ( EAA ) : EAA ≥ 0.6 -0.9 &gt; or IL6 &gt; 150 pg/mL

        Exclusion Criteria:

          -  Pregnancy;

          -  Age &lt; 18 years 75&gt;

          -  Chronic Renal failure or previous CRRT

          -  Immunological disease or immunosuppressive drugs or EAA &lt; 0.6 with IL 6 in the normal
             range.

          -  CGS &lt; 8 due to hemorrhagic or ischemic event.

          -  ECMO v-v or a-v or ECCO2 removal.

          -  No resolution of the surgical source of infection

          -  Terminal condition

          -  Any contraindication to heparin and other anticoagulant.

          -  Other pathological conditions in which the oXiris filter is not indicated and other
             therapeutic options are required. (eg . Hepatic failure , Cardiac failure )
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Franco Turani</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FRANCO TURANI, MD</last_name>
      <phone>00393484725073</phone>
      <email>turani.franco44@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Malard B, Lambert C, Kellum JA. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices. Intensive Care Med Exp. 2018 May 4;6(1):12. doi: 10.1186/s40635-018-0177-2.</citation>
    <PMID>29728790</PMID>
  </reference>
  <reference>
    <citation>Turani F, Barchetta R, Falco M, Busatti S, Weltert L. Continuous Renal Replacement Therapy with the Adsorbing Filter oXiris in Septic Patients: A Case Series. Blood Purif. 2019;47 Suppl 3:1-5. doi: 10.1159/000499589. Epub 2019 Apr 12. Review.</citation>
    <PMID>30982024</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 11, 2019</study_first_submitted>
  <study_first_submitted_qc>April 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>April 30, 2019</last_update_submitted>
  <last_update_submitted_qc>April 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Rome Tor Vergata</investigator_affiliation>
    <investigator_full_name>FRANCO TURANI</investigator_full_name>
    <investigator_title>Adjunt Professor of Anesthesia and Intensive Care</investigator_title>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Acute Renal Failure</keyword>
  <keyword>Extra Corporeal Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

